[A25-126] Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Addendum to Project A25-67
Last updated 06.11.2025
Project no.:
A25-126
Commission:
Commission awarded on 23.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Prophylaxis of cytomegalovirus reactivation and disease in paediatric patients with a body weight of at least 5 kg who are cytomegalovirus-seropositive recipients of an allogeneic haematopoietic stem cell transplant
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-126
| Project no. | Title | Status |
|---|---|---|
| A25-67 | Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-11-06 A G-BA decision was published.